EFFICIENT DESIGNS FOR RANDOMIZED TRIALS WITH RESPONSE AS AN END-POINT

被引：0
|
作者：
WIEAND, S [1 ]
THERNEAU, T [1 ]
机构：
[1] MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905
来源：
CONTROLLED CLINICAL TRIALS | 1986年 / 7卷 / 03期
关键词：
D O I：
10.1016/0197-2456(86)90077-2
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：236 / 236
页数：1
相关论文
共 50 条
  • [31] Progression-free survival as an end-point in clinical trials of biotherapeutic agents
    Bergmann, Lothar
    Hirschfeld, Steven
    Morris, Charles
    Palmeri, Sergio
    Stone, Andrew
    EJC SUPPLEMENTS, 2007, 5 (09): : 23 - 28
  • [32] Endothelial function as an end-point in interventional trials: Concepts, methods and current data
    Luscher, TF
    Noll, G
    JOURNAL OF HYPERTENSION, 1996, 14 : S111 - S119
  • [33] MORBIDITY OR MORTALITY AS END-POINT FOR CLINICAL-TRIALS IN INTENSIVE-CARE
    DECRUYENAERE, J
    DEDEYNE, C
    POELAERT, J
    COLARDYN, F
    LANCET, 1995, 345 (8955): : 986 - 987
  • [34] END-POINT OF A PRESERVATION PROCESS
    PFLUG, IJ
    JOURNAL OF FOOD PROTECTION, 1987, 50 (04) : 347 - 351
  • [35] BOF END-POINT DETERMINATION
    MUCCIARDI, F
    OLEARY, K
    CIM BULLETIN, 1985, 78 (878): : 74 - 74
  • [36] QUALITY-OF-LIFE AS A THERAPEUTIC END-POINT - AN ANALYSIS OF THERAPEUTIC TRIALS IN HYPERTENSION
    HOLLENBERG, NK
    TESTA, M
    WILLIAMS, GH
    DRUG SAFETY, 1991, 6 (02) : 83 - 93
  • [37] THE IMPACT OF END-POINT MEASURES IN RHEUMATOID-ARTHRITIS CLINICAL-TRIALS
    VANDERHEIDE, A
    JACOBS, JWG
    DINANT, HJ
    BIJLSMA, JWJ
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 1992, 21 (05) : 287 - 294
  • [38] MEASUREMENT OF LEFT-VENTRICULAR FUNCTION AS AN END-POINT IN TRIALS OF THROMBOLYTIC THERAPY
    SHEEHAN, FH
    CORONARY ARTERY DISEASE, 1990, 1 (01) : 13 - 22
  • [39] SURROGATE END-POINT BIOMARKERS FOR PHASE-II CANCER CHEMOPREVENTION TRIALS
    KELLOFF, GJ
    BOONE, CW
    CROWELL, JA
    STEELE, VE
    LUBET, R
    DOODY, LA
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 1 - 9
  • [40] Informative censoring of surrogate end-point data in phase 3 oncology trials
    Gilboa, Shai
    Pras, Yarden
    Mataraso, Aviv
    Bomze, David
    Markel, Gal
    Meirson, Tomer
    EUROPEAN JOURNAL OF CANCER, 2021, 153 : 190 - 202
12345